secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2026-06-30T20:01:15+00:00
Accession:  0001193125-26-290447
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology appoints Scott Garland as Chairman, Michael Listgarten as General Counsel; co-founder resigns
--------------------------------------------------------------------------------

- Co-founder Corey Goodman resigned as Chairman and board member effective June 29, 2026, for personal reasons.
- Scott Garland, independent director since Nov 2022, appointed Chairman of the Board.
- Michael Listgarten appointed General Counsel, effective immediately.
- Company advancing evorpacept into late-stage development and progressing ALX2004.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/0001193125-26-290447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/alxo-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-290447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer